Estimated glomerular filtration rate, albuminuria and adverse outcomes

Morgan E Grams, MD PhD1; Josef Coresh, MD PhD; Kunihiro Matsushita, MD, PhD2; Shoshana H Balfe, PhD2; Yingying Sang, MD2; Aditya Surapaneni, PhD2; Natalia Alencar de Pinho, PhD2; Amanda Anderson, PhD2; Lawrence J Appel, MD2; Johan Arnlov, MD PhD2; Fereidoun Azizi, MD2; Nisha Bansal, MD1; Samira Bell, MD5; Henk J G Bilo, MD PhD6; Nigel J Brunk ML, MD PhD10; Juan J Carrero, PhD11; Steve Chadbourn, MD PhD12; John Chalmers, MD PhD13; Jing Chen, MSc MD14; Elizabeth Ciemins, MPH PhD15; Massimo Crillo, MD16; Natalie Ebert, MPH MD17; Marie Evans, MD PhD18; Alejandro Ferreiro, MD19; Edouard L Fu, PhD20; Masafumi Fukagawa, MD, PhD21; Jamie A Green, MD22; Orlando Gutierrez, MD23; William G Herrington, MD24; Shih-Jen Hwang, PhD25; Lesley A Inker, MD26; Kunitoshi Iseki, MD27; Taezen Jafar, MPH MD28; Simerjot K Jassal, MD29; Vivekanand Jha, MD DM30; Aya Kadota, MD PhD31; Ronit Katz, DPhil32; Anna Köttgen, MD MPH33; Tsuneo Konta, MD34; Florian Kronenberg, MD35; Brian J Lee, MD36; Jennifer Lees, MBChB PhD37; Adeera Levin, MD38; Helen C Looker, MBBS39; Rupert Major, MD PhD40; Chell Melzer Cohen, MSc41; Makiko Mieno, PhD42; Mariko Miyazaki, MD PhD43; Olivier Moranne, MD PhD44; Isao Muraki, MD PhD45; David Naimark, MD MSc46; Dorothea Nitsch, MD47; Wonsuk Oh, PhD48; Michelle Pena, MPH PhD49; Tanjala S Purnell, MPH PhD50; Charumathi Sabanayagam, MPH MD PhD51; Michihiro Satoh, PhD52; Simon Sawhney, MD PhD53; Elke Schaefferner, MSc MD17; Ben Schöttker, PhD54; Jenny I Shen, MD55; Michael G Shipak, MPH MD56; Smeeta Sinha, MBChB PhD57; Benicité Stengel, MD PhD58; Keiichi Sumida, MPH MD PhD59; Marcello Tonelli, MD28; Jose M Valdivielso, PhD60; Arjan D van Zuiilen, MD61; Frank LJ Visseren, MD PhD62; Angela Yee-Moon Wang, MD PhD63; Chi-Pang Wen, MD DrPh64; David C Wheeler, MD64; Hiroshi Yatsuji, PhD65; Kunihiro Yamagata, MD PhD66; Jae won Yang, MD67; Ann Young, MD PhD68; Haitao Zhang, PhD69; Luxia Zhang, MPH MD70; Andrew S Levey, MD71; Ron T Gansevoort, MD PhD72

For the CKD Prognosis Consortium

Correspondence:
Dr. Morgan Grams, MD, PhD, New York University Grossman School of Medicine, Department of Medicine, Division of Precision Medicine, 227 E 30th Street, #825, New York, NY 10016 and the Chronic Kidney Disease Prognosis Consortium Data Coordinating Center, 2024 East Monument Street, Baltimore, MD 21205. Email: ckdpc@nih.gov.

1 New York University Grossman School of Medicine, Department of Medicine, Division of Precision Medicine, New York, New York, USA
2 Department of Epidemiology, Bloomberg School of Public Health, and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
3 Centre for research in Epidemiology and Population Health (CESP), Paris-Saclay University, Inserm U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France
4 Tulane University School of Public Health and Tropical Medicine, New Orleans, LA
5 School of Health and Social Studies, Dalarna University, Falun, Sweden and Department of Neurobiology, Care Sciences and Society, Family Medicine and Primary Care Unit, Karolinska Institutet, Huddinge, Sweden
6 Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran
7 Division of Nephrology, University of Washington, Seattle, Washington, USA
8 Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, United Kingdom
9 Diabetes Centre, Isala, and Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Netherlands

Commented [GM1]: To the Editors: We are ok with having the single author CKD Prognosis Consortium with these authors listed in the back as Writing Group and the other group of collaborators being “For the CKD Prognosis Consortium”
10 Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom; John Walls Renal Unit, Leicester General Hospital, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
11 Department of Medical Epidemiology and Biostatistics, Karolinska Institute, and Department of Clinical Science, Danderyd Hospital, Sweden
12 Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
13 The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia; School of Public Health, Imperial College, London, UK; and Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India
14 Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA
15 AMGA (American Medical Group Association), Alexandria, Virginia, USA
16 Dept. "Scuola Medica Salernitana", University of Salerno, Fisciano (SA), Italy
17 Institute of Public Health, Charité University Medicine, Berlin, Germany
18 Department of Renal Medicine, CLINTEC, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
19 Departamento de Nefrología, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
20 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
21 Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan
22 Department of Nephrology, Geisinger Commonwealth School of Medicine, Danville, Pennsylvania, USA; Center for Kidney Health Research, Geisinger, Danville, Pennsylvania, USA
23 Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama
24 Medical Research Council Population Health Research Unit, University of Oxford, United Kingdom; Clinical Trial Service Unit, University of Oxford, United Kingdom
25 Framingham Heart Study, MA; Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
26 Division of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA
27 Okinawa Heart and Renal Association, Okinawa, Japan
28 Programme in Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore; Duke Global Health Institute, Duke University, Durham, North Carolina, USA
29 University of California San Diego, La Jolla, CA, USA; San Diego VA Health Care System, San Diego, California, USA
30 George Institute for Global Health India, New Delhi, India; The George Institute for Global Health, School of Public Health, Imperial College London, United Kingdom
31 Department of Public Health, NCS Epidemiology Research Center, Shiga University of Medical Science, Otsu, Japan
32 Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA
33 Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany
34 Department of Public Health and Hygiene, Yamagata University Faculty of Medicine, Yamagata, Japan
35 Institute of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria
36 Kaiser Permanente, Hawaii Region, and Moanalua Medical Center, Honolulu, Hawaii, USA
37 School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom; Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, United Kingdom
38 Division of Nephrology, University of British Columbia, Vancouver, Canada
39 Chronic Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, USA
40 Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel-Aviv, Israel
41 Department of Medical Informatics, Center for Information, Jichi Medical University, Tochigi, Japan
42 Department of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University
Graduate School of Medicine, Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan
43 Service de Néphrologie Dialyse Apherèse, Nîmes Hôpital Universitaire, Nîmes, France; IDESP, UMR-INSERM, Montpellier, France
44 Public Health, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
45 Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada
46 London School of Hygiene & Tropical Medicine, London, United Kingdom
47 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA
48 Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
49 Division of Transplantation, Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD; Johns Hopkins Center for Health Equity, Johns Hopkins University, Baltimore, Maryland, USA
50 Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore; Ophthalmology and Visual Sciences Academic Clinical Programme (EYE-ACP), Duke-NUS Medical School, Singapore, Singapore
51 Division of Public Health, Hygiene, and Epidemiology Tohoku Medical and Pharmaceutical University Sendai, Japan
52 Aberdeen Centre for Health Data Science, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, Scotland; NHS Grampian, Aberdeen, Scotland
53 Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany
54 Department of Medicine, David Geffen School of Medicine, Los Angeles, California, USA; The Lundquist Institute, Harbor-UCLA Medical Center, Torrance, California, USA
55 Kidney Health Research Collaborative, Department of Medicine, University of California San Francisco, San Francisco, California, USA; General Internal Medicine Division, Medical Service, San Francisco Veterans Affairs Health Care System, San Francisco, California, USA
56 Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom
57 Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA
58 Department of Medicine, University of Calgary, Calgary, Alberta, Canada
59 Vascular & Renal Translational Research Group, IRBLleida, Spain and Spanish Research Network for Renal Diseases, Lleida, Spain
60 University Medical Center Utrecht, Department of Nephrology and Hypertension, Utrecht, Netherlands
61 Department of Vascular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
62 Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
Key words: Glomerular filtration rate, creatinine, cystatin C, GFR estimating equations, chronic kidney disease, albuminuria

Manuscript word count: 3281

Date of revision: August 2, 2023
**Key Points (100 word limit)**

**Question:** Are lower values for eGFR (based on either creatinine alone or creatinine and cystatin) and higher values for albuminuria associated with adverse kidney and cardiovascular outcomes?

**Findings:** In this retrospective individual-level data analysis of 27,503,140 participants from 114 cohorts, lower eGFR and higher albuminuria were each associated with higher rates of adverse kidney outcomes including kidney failure with replacement therapy and acute kidney injury. They were also associated with adverse cardiovascular outcomes including cardiovascular mortality, heart failure, and atrial fibrillation.

**Meaning:** Lower eGFR values and more severe albuminuria were associated with multiple adverse outcomes.

**Commented [GM2]:** To the Editor: I wonder if removing reference to cystatin C is a mistake since that is the major novelty of this paper. Could add to findings or rewrite the question as I did, editing the meaning section to keep to <100 words.

**Deleted:** that included kidney failure, cardiovascular mortality, heart failure, and atrial fibrillation.
Abstract

Importance: Chronic kidney disease (low eGFR or albuminuria) affects approximately 14% of people in the United States.

Objective: To evaluate associations of lower eGFR using creatinine alone (eGFRcr), lower eGFR using creatinine combined with cystatin C (eGFRcr-cys), and higher albuminuria with adverse kidney outcomes, cardiovascular outcomes, and other health outcomes.

Design, setting, participants: Retrospective individual-level data analysis of 27,503,140 participants from 114 global cohorts (eGFRcr) and 720,736 participants from 20 cohorts (eGFRcr-cys) and 9,067,753 participants from 114 cohorts (albuminuria) from 1980 to 2021.

Exposures: CKD-EPI 2021 equations for eGFRcr and eGFRcr-cys; albuminuria estimated as urine albumin-to-creatinine ratio (ACR).

Main outcomes and measures: The risk of kidney failure with replacement therapy, all-cause mortality, cardiovascular mortality, acute kidney injury, any hospitalization, coronary heart disease, stroke, heart failure, atrial fibrillation, and peripheral artery disease. Analyses were performed within each cohort and summarized with random-effect meta-analyses.

Results: Within the eGFRcr population (mean age: 54 years, 51% women), mean eGFRcr was 90 ml/min/1.73 m² (SD, 22) and median ACR was 11 mg/g (interquartile range 8-16 mg/g).

Within the eGFRcr-cys population (mean age: 59 years, 53% women), mean eGFRcr-cys was 88 ml/min/1.73 m² (SD, 22) and median ACR was 9 mg/g (interquartile range 6-18 mg/g).

Lower eGFR (whether based on eGFRcr or eGFRcr-cys) and higher ACR were each associated with higher risk of all ten adverse outcomes, including in the mildest categories of CKD. For example, among people with ACR <10 mg/g, an eGFRcr 45-59 ml/min/1.73 m² was associated with significantly higher hospitalization rates, compared to eGFR 90-105 ml/min/1.73 m².
(adjusted hazard ratio 1.28, 95% CI: 1.24-1.32; 101 vs. 79 events per 1000 person-years; excess absolute risk 22 events per 1000 person-years; 95% CI: 19 to 25).

Conclusions and relevance: In this retrospective analysis of 114 cohorts, lower eGFRcr, lower eGFRcr-cys, and higher ACR were each associated with increased rates of 10 adverse outcomes, including adverse kidney outcomes, cardiovascular diseases, and hospitalization.
**Introduction**

Chronic kidney disease (CKD), defined by albuminuria ≥30 mg per day or glomerular filtration rate (GFR) <60 ml/min/1.73 m² that persists for at least three months, affects approximately 14% of adults in the US.¹ Both lower estimated GFR (eGFR) values and more severe albuminuria have been associated with higher rates of kidney failure with replacement therapy, acute kidney injury, all-cause and cardiovascular mortality.²⁻⁶

This study evaluated associations of albuminuria, eGFR, and the combination of albuminuria and eGFR with 10 adverse health outcomes, consisting of incident kidney failure with replacement therapy, all-cause mortality, cardiovascular mortality, acute kidney injury, hospitalization, coronary heart disease, stroke, heart failure, atrial fibrillation, and peripheral artery disease. Associations were evaluated within subgroups of age, sex, and presence of diabetes and cardiovascular disease. GFR was assessed using race-free equations incorporating creatinine alone (eGFRcr) or both creatinine and cystatin C (eGFRcr-cys), and pre-specified analyses included evaluating whether eGFRcr-cys was more strongly associated with adverse outcomes compared to eGFRcr.

**Methods**

**Study Population**

Investigators in the CKD Prognosis Consortium (ckdpc.org) were invited to participate in the current meta-analysis if their represented cohorts included participants with both eGFR and albuminuria as well as ≥50 events of at least one outcome. 120 cohorts were evaluated; two did not agree to participate, and four were unable to send data or run code within the time allotted.
leaving 114 participating cohorts. Data sources included 37 observational studies or clinical trials of participants identified from the general population, 49 electronic health record databases, and 28 observational studies or clinical trials of people with CKD. Additional information on included cohorts is included in the Supplemental Appendix 1. For measures of prevalence and absolute incidence of adverse outcomes, we used Optum Labs Data Warehouse (OLDW), a data set with de-identified administrative claims and electronic health record (EHR) data on patients followed longitudinally. The EHR-derived data included a subset of data that was normalized and standardized into a single database.11 The study was approved by the Institutional Review Board (IRB) at the Johns Hopkins Bloomberg School of Public Health. Data were pre-existing and de-identified, but in accordance with individual cohort policies, the study underwent expedited IRB approval. The IRB waived the requirement for informed consent.

Kidney Measures

All participants had serum creatinine measurements with eGFRcr estimated at baseline using the race-free CKD-EPI 2021 creatinine equation [overall population (eGFRcr population)].8 A subset also had cystatin C measurements with eGFRcr-cys estimated using the CKD-EPI 2021 creatinine-cystatin C equation [population with cystatin C (eGFRcr-cys population)]. Methods for creatinine and cystatin C for each cohort are described in Supplemental Appendix 1.12-14 eGFR was categorized as follows: ≥105, 90-104, 60-89, 45-59, 30-44,15-29, and <15 ml/min/1.73 m².

Albuminuria was measured and calculated as urine albumin-to-creatinine ratio (ACR), urine protein-to-creatinine ratio, or dipstick proteinuria. For the former two methods, both spot and 24-hour collections were accepted. For the latter two methods, values were extrapolated to ACR.
using a previously published multivariable conversion equation. In the categorical analyses, dipstick proteinuria was classified to ACR categories in the following manner: negative to <10 mg/g, trace to 10-29 mg/g, 1+ to 30-99 mg/g, 2+ to 300-999 mg/g, 3+ or 4+ to 1000 mg/g and higher. In sensitivity analyses without dipstick values, all dipstick measures were classified in the missing ACR category.

Outcomes

The following outcomes were requested from each cohort: all-cause mortality, cardiovascular mortality (death due to cardiovascular disease), kidney failure with replacement therapy (receipt of chronic dialysis or kidney transplantation), all-cause hospitalization, and hospitalizations for stroke (ischemic or hemorrhagic), myocardial infarction, heart failure (any hospitalization or death with heart failure), acute kidney injury, atrial fibrillation, and peripheral artery disease. Some cohorts linked to the United States Renal Data System (USRDS) in order to ascertain kidney failure with replacement therapy, some cohorts performed expert adjudication for specific outcomes, and some identified outcomes based on ICD-coding alone. Cohort-specific outcome definitions are listed in the Supplemental Appendix 1. Individuals with a prior history of the outcome were excluded from the analyses of incident events. Each cohort contributed between 1 and 10 analyses, depending on the outcomes available for each cohort. General population cohorts with fewer than fifty events for a specific outcome and CKD cohorts with fewer than 25 events were excluded from the meta-analysis for the corresponding outcome.

Statistical Analyses

Each analysis was performed separately within each cohort. Hazard ratios were then meta-analyzed using random-effect models. Categories of eGFR (<15, 15-29, 30-44, 45-59, 60-89,
90-104, and 105+ ml/min/1.73 m²) and ACR (<10, 10-29, 30-99, 300-999, and 1000+ mg/g) at a single visit were used. Interaction terms included all combinations of the eGFR and ACR categories (e.g., the product terms of eGFR <15 ml/min/1.73 m² and ACR <10 mg/g, eGFR 15-29 ml/min/1.73 m² and ACR <10 mg/g, eGFR 30-44 ml/min/1.73 m² and ACR <10 mg/g, etc.).

Because relatively few participants had data to contribute to the eGFRcr-cys analyses, less common categories of eGFR and ACR were combined to ensure adequate numbers of events. Hence, the two lowest categories of eGFR were combined (<15 and 15-29 ml/min/1.73 m²), as were the two highest categories of ACR (ACR 300-999 and 1000+ mg/g). Model adjustment differed for different outcomes and included a subset of the following covariates: age, sex, smoking status (current, former, never), systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, body-mass index, use of anti-hypertensive medications, and a medical history of diabetes, coronary heart disease, stroke, heart failure, atrial fibrillation, peripheral artery disease, cancer, and chronic obstructive pulmonary disease, where relevant (e.g., an analysis of incident peripheral artery disease as an outcome would not include peripheral artery disease as an adjustment variable). All covariate definitions and models are detailed in Supplemental Appendix 1. Quantitative covariates were included in the model using a continuous scale. Missing data for albuminuria were treated as a separate category when missingness exceeded 10% in a given cohort, otherwise complete case analysis was performed. For other variables, the extent and handling of missing data are detailed in the Table S1 and Supplemental Appendix 1. The statistical model used for all outcomes was Cox proportional hazards regression. For categorical analyses, hazard ratios were calculated for the general population cohorts and for the electronic health record cohorts, since the CKD cohorts lacked participants in the reference cell (eGFR 90-104 ml/min/1.73 m² and ACR <10 mg/g), and models were performed overall and by stratum of age (<65 years, 65+ years) and sex (female, male).
To facilitate comparison of associations across cohorts, outcomes, and by filtration marker (eGFRcr vs. eGFRcr-cys), eGFR and ACR were also modeled continuously: eGFR with linear spline terms with knots at 60 and 105 ml/min/1.73 m$^2$, and ACR with log-transformation. Model parameters were otherwise identical to those of the categorical analyses. Continuous analyses were performed in all cohorts, including the general population, electronic health record, and CKD cohorts. Beta coefficients from Cox proportional hazards models were then meta-analyzed with random effects, as above. Forest plots were examined to assess heterogeneity of effect sizes across cohorts and cohort characteristics, and subgroup analyses by age, sex, diabetes, and presence of cardiovascular disease were performed. In sensitivity analyses, continuous associations were also examined using other estimating equations for GFR, including previous CKD-EPI equations$^{16,17}$ but using only the non-Black race value (CKD-EPI 2009 eGFRcr and CKD-EPI 2012 eGFRcr-cys) and European Kidney Function Collaboration equations$^{18}$ (EKFC eGFRcr and eGFRcr-cys).

To determine whether associations were similar across populations or subgroups of populations, comparisons of meta-analyzed beta coefficients (log-hazard ratios) within each combined category of eGFR and ACR were performed using Wilcoxon matched pair signed rank tests, and differences between populations in beta coefficients of the combined eGFR and ACR categories were summarized using median and interquartile interval. A p-value < .05 was considered statistically different.

The largest cohort, the Optum Labs Data Warehouse, an electronic health record population in the US, was used to estimate prevalence of eGFR and ACR categories and the unadjusted
incidence rates of each adverse outcome within categories of eGFR and ACR. For these analyses, a single measure of eGFR and albuminuria were used. The incidence of adverse outcomes was estimated individually within each of the 39 health systems and summarized as median value across each health system (e.g., 19 health systems had higher incidence rates and 19 health systems had lower incidence rates) and 25th-75th percentile. Adjusted excess incidence (i.e., the difference in incidence comparing one combined eGFR and ACR category to the reference) was estimated by treating incidence rates in the median health system in the reference cell among OLDW cohorts as a constant and combining with the meta-analyzed hazard ratios for each cell in the categorical analysis of eGFRcr.

All analyses were conducted using Stata MP 16.1. All statistical testing was two-sided. Statistical significance was determined as p < .05.

Results

Study Population

Of the 120 cohorts evaluated for inclusion, 114 cohorts including 27,503,140 people had data available for eGFRcr and were included in analyses. Among these participants, mean age was 54 years (standard deviation (SD), 17), 51% were female, mean eGFRcr was 90 (SD, 22) ml/min/1.73 m², and 33.0% had measures of albuminuria. Of those with albuminuria measures, median ACR was 11 mg/g (interquartile range 8-16 mg/g). In the eGFRcr population, the number of cohorts contributing to each outcome ranged from 52 (acute kidney injury) to 108 (all-cause mortality). Rates of adverse outcomes were lowest for peripheral artery disease.
of 62 cohorts, 1.4 events per 1,000 person-years) and kidney failure with replacement therapy (median of 83 cohorts, 1.3 events per 1,000 person-years) and the highest for hospitalization (median of 52 cohorts, 94 events per 1,000 person-years) (Table S2).

20 cohorts with 721,394 people included data for cystatin C (eGFRcr-cys population). For these participants, mean age was 59 years (SD, 12), 53% were female, mean eGFRcr was 89 (SD, 20) ml/min/1.73 m² and eGFRcr-cys was 88 (22) ml/min/1.73 m², and 44.4% had measures of albuminuria. Among those with albuminuria measures, median ACR was 9 mg/g (interquartile range 6-18 mg/g) (Table 1). Clinical characteristics for each cohort are shown in Table S3 (eGFRcr population) and Table S4 (eGFRcr-cys population). Most participants who were missing albuminuria data came from EHR cohorts (95.4% of the eGFRcr population and 99.8% of the eGFRcr-cys population).

Overall, the mean follow-up time was 4.8 years (SD, 3.2). For analyses of eGFRcr-cys, mean follow-up was 10.8 years (SD, 4.1) and the number of cohorts contributing data (ranged from 3 (for hospitalizations) to 20 (for all-cause mortality)) (Table S5).

Analyses According to eGFRcr and ACR

In the categorical analyses of eGFRcr, compared to the reference of eGFR of 90-105 ml/min/1.73 m², lower eGFR categories below eGFR 60 ml/min/1.73 m² were significantly associated with higher risk of each outcome. Compared to the reference of ACR <10 mg/g, higher ACR categories were associated with higher rates of each outcome (Figure 1). Risks among people with missing ACR were comparable to those within the ACR 10-29 mg/g.
category [median (interquartile interval) difference in log-hazard ratios: -0.03 (-0.11 to 0.09), p = 0.39 (Table S6). The patterns of risk associations were similar across each age category and among men and women, although relative risks were weaker in older compared to younger age and very slightly stronger in women compared with men [median (IQI) difference in log-hazard ratios, older vs. younger age groups, -0.45 (-0.70 to -0.14), p < 0.001; women vs. men: 0.04 (-0.05 to 0.13), p < 0.001] (Table S7).

Compared to eGFRcr 90-105 ml/min/1.73 m², CKD category G3a (eGFRcr 45-59 ml/min/1.73 m²) was significantly associated with higher adjusted hazard ratios of each outcome, even among people with ACR <10 mg/g, ACR 10 to <30 mg/g, or missing ACR (Table 2). When stratified by age and sex, relative risks for CKD category G3a were smaller among older adults compared to younger adults [median (IQI) difference in log-hazard ratios, older vs. younger age groups, -0.36 (-0.49 to -0.27), p < 0.001]; however, all remained statistically significant except for hospitalizations among older adults in people with missing data for ACR. Relative risks between men and women were not significantly different [median (IQI) difference in log-hazard ratios, women vs. men, 0.02 (-0.04 to 0.07), p = 0.19] (Table S8).

In continuous analyses, hazard ratios for the spline term for lower eGFR below 60 ml/min/1.73 m² and 8-fold higher ACR were highest for kidney failure with replacement therapy [hazard ratio for eGFR<60 per 15 ml/min/1.73 m² lower, 3.89 (95% CI: 3.73, 4.06)], with all (eGFR) or nearly all (ACR) associations statistically significant in the individual cohorts (Table S9, Figure S1). In sensitivity analyses excluding albuminuria measured by dipstick, ACR associations were not statistically different from those when dipstick measures were included [median (IQI) difference

Commented [GM7]: To the Editors: Apologies, but the edits make the statements incorrect. This refers to continuous, not categorical analyses.

Commented [GM8]: To the Editors: Apologies, but the edits make the statements incorrect. I rejected the changes.
in log-hazard ratios, excluding vs. including: -0.02 (-0.02 to -0.004), p = .06 (Table S10). Hazard ratios by subgroup of age, sex, diabetes, and cardiovascular disease are shown in Table S11.

**Analyses According to eGFRcr-cys and ACR**

In categorical analyses of eGFRcr-cys, compared to the reference of eGFR of 90-105 ml/min/1.73 m², lower eGFR categories below eGFR 60 ml/min/1.73 m² were significantly associated with higher risk of each outcome. Compared to the reference of ACR <10 mg/g, higher ACR categories were associated with higher rates of each outcome (Figure 2, Table S12). Associations remained statistically significant in subset analyses by age and sex, with weaker relative risks in older compared with younger adults [median (IQI) difference in log-hazard ratios, older vs. younger, -0.14 (-0.36 to 0.03), p<.001; women vs. men: -0.002 (-0.10 to 0.11), p = .53] (Table S13). The differences in adjusted hazard ratios for eGFRcr-cys between older and younger age groups was smaller than those seen with eGFRcr [median (IQI) difference in differences, eGFRcr-cys vs. eGFRcr -0.16 (-0.34 to -0.01), p<.001] (Table S13). Risk for all outcomes was increased in CKD category G3a (eGFRcr-cys 45-59 ml/min/1.73 m²) even among people with levels of albuminuria of <10 mg/g, and these risks remained statistically significant in analyses of subsets by age and sex (Table 3, Table S14). Compared to analyses with eGFRcr, risk associations with eGFRcr-cys were stronger and less U-shaped [median (IQI) difference in log-hazard ratios, 0.10 (0.02 to 0.21), p<.001] (Figure 3).

Associations with alternative estimating equations for GFR are shown in Table S15. The alternative estimating equations were highly correlated with eGFR estimated using CKD-EPI 2021 in all cohorts (range of Pearson correlations between eGFRcr estimated with CKD-EPI 2021 and EKFC, 0.98-1; between eGFRcr-cys estimated with CKD-EPI 2021 and EKFC, 0.93-
0.99; between eGFRcr estimated with CKD-EPI 2021 and CKD-EPI 2009 NB, 0.99-1; between eGFRcr-cys estimated with CKD-EPI 2021 and CKD-EPI 2012 NB 0.996-1).

Prevalence of CKD and Incidence of Adverse Outcomes

In a large, national US electronic health record database, 63% of people were missing a measure of albuminuria (including dipstick measures). The prevalence of each category of eGFRcr was similar with and without the inclusion of those missing albuminuria: for example, 9.6% and 10% of individuals had eGFRcr <60 ml/min/1.73 m², respectively. Among those with measures of albuminuria, the prevalence of ACR 30-299 mg/g (category A2), ACR 300-999 mg/g and ACR 1000+ mg/g was 9.9%, 3.1%, and 1.2%, respectively (Table S1).

The unadjusted incidence rate of each outcome was higher with more severe categories of eGFR and ACR. Hospitalizations were the most common adverse outcome. Rates per 1000 person-years in the reference group (eGFR 90-104 ml/min/1.73m² and ACR<10 mg/g) from most common to least common were: hospitalizations 79, all-cause mortality 11, acute kidney injury 4.5, atrial fibrillation 4.0, heart failure 3.9, cardiovascular mortality 2.7, stroke 2.1, myocardial infarction 1.7, peripheral artery disease 0.6 and kidney failure with replacement therapy 0.1 (Table S17). For the most severe CKD categories (eGFR<15 ml/min/1.73m² and ACR 1000+ mg/g), the highest rates of adverse outcomes per 1000 person-years were hospitalizations (504), mortality (187) and kidney failure with replacement therapy (175). Adjusted excess mortality is shown in Table S18. Unadjusted incidence rates by age and sex are shown in Table S19-22.
Discussion

This individual-participant data meta-analysis of more than 27 million people evaluated associations of eGFR and albuminuria with ten adverse outcomes that included kidney outcomes, all-cause mortality, cardiovascular mortality, hospitalizations, and other cardiovascular events. There were strong, graded associations with lower eGFR and adverse outcomes for the new, race-free 2021 CKD-EPI eGFRcr equation and also when cystatin C was included as an additional filtration marker in eGFRcr-cys. The pattern of associations persisted irrespective of age, sex, diabetes, and cardiovascular disease and were stronger for eGFRcr-cys as compared with eGFRcr. This work supports recent recommendations to increase the use of cystatin C in clinical practice.9,10

Prior meta-analyses of eGFR and albuminuria with adverse outcomes evaluated only 5 adverse outcomes in 1.2 million participants and 21 cohorts from 14 countries.2-6 These reports used eGFRcr estimated with the MDRD Study equation, which includes race, and an unvalidated equation to impute urine ACR from urine protein-to-creatinine ratios. In this study, eGFR was calculated using the race-free estimating equations for both eGFRcr and eGFRcr-cys per 2021 recommendations by the National Kidney Foundation and American Society of Nephrology.9,10 ACR was imputed from urine protein-to-creatinine ratio and urine dipstick protein using a validated equation.7,19 This study adds to current literature by providing strong evidence for the classification and risk stratification of CKD using the most up-to-date estimates of GFR, more categories of albuminuria, and additional cardiovascular outcomes. The use of 114 cohorts from across the world enhances generalizability of the results.
The results underscore the importance of albuminuria in risk assessment. Even mildly elevated albuminuria (A2: ACR 30-299 mg/g) was statistically significantly associated with increased risk for all outcomes. The adjusted excess risk of mortality associated with category A3 (ACR 300-999 mg/g) at normal eGFR was comparable to that of stage 1 colon cancer (17 deaths per 1000 person-years vs. 5-year survival rate of 91%). Similar to previous observations, however, this study demonstrates low rates of albuminuria measurement in electronic health records.

Some guidelines recommend cystatin C testing in patients with CKD, and others discourage measurement of cystatin C. The current study provides evidence as to the potential utility of the combined eGFRcr-cys equation. With eGFRcr, there was a U-shape association of eGFR with study outcomes, with higher risk in both lower eGFRcr <60 ml/min/1.73 m² and higher eGFRcr >105 ml/min/1.73 m². This finding may indicate imprecision and systematic overestimation of GFR among people who progress to adverse events (thus contributing to the U-shaped curve). With eGFRcr-cys, there was a more linear risk relationship. Both creatinine and cystatin C values are affected by clinical characteristics independent of GFR, and the most widely recognized non-GFR determinant for creatinine is muscle mass. Persons with low muscle mass, on average, have higher eGFRcr than eGFRcys. Differences in relative risks between eGFRcr and eGFRcr-cys were observed among older adults, suggesting that when clinically available, additional use of cystatin C could better identify high-risk individuals, particularly among older populations.

This study has several strengths. First, the sample size was large and included people from multiple countries. Second, the most recent eGFR equations were evaluated. Third, results suggested that deviations in risk associations across type, geographical location, or
characteristic of cohorts were unlikely. Fourth, subgroup analyses demonstrated the higher risk associated with lower eGFR and higher albuminuria across categories of age, sex, presence of diabetes, and history of cardiovascular disease.

Limitations

This study has several limitations. First, other estimating equations of eGFR were not comprehensively tested. Second, the included cohorts used different study designs and protocols for outcome ascertainment. Outcomes were often based on ICD codes, which have variable sensitivity and specificity for each outcome measure. Third, cystatin C was available in only a subset of cohorts. Fourth, data were observational and causal inferences should not be made. Fifth, although findings support the use of eGFRcys in the detection and staging of CKD, cystatin C is not widely available and may be expensive. Sixth, some variables such as baseline heart failure were missing from several cohorts, and may have confounded the relationship between eGFR and outcomes, particularly acute kidney injury.

Conclusion

In this retrospective analysis of 114 cohorts, lower eGFRcys, lower eGFRcys-cys, and higher ACR were each associated with increased rates of 10 adverse outcomes, including adverse kidney outcomes, cardiovascular diseases, and hospitalization.

Acknowledgements
CKD-PC investigators/collaborators (cohort acronyms/abbreviations are listed in Supplemental Appendix 2. No personal compensation was received for this study; participating cohorts received modest compensation for preparation of data sent to CKD-PC.:)

Victoria Ngai, Tang Ka Tak; ICES KDT: Amit X. Garg, Eric McArthur, Ann Young; ICKD:

Vivekanand Jha, Ashok Kumar Yadav, Vivek Kumar; JHS: April P Carson, Bessie Young,
Clarissa Diamantidis, Yuan-I Min, Tanjala S Purnell; JMS: Shizukiyo Ishikawa, Makiko Meno;
J-SHC: Kunihiro Yamagata, Kunitoshi Iseki, Koichi Asahi, Tsuneo Konta; KP Hawaii: Brian J Lee;
LCC: Nigel J Brunskill, Laura Gray, Rupert Major, James Medcalf; Maccabi: Gabriel Chodick,
Cheli Melzer Cohen; MASTERPLAN: Jack FM Wetzels, Peter J Blankestijn, Arjan D van Zuilen;
MDRD: Lesley A Inker, Andrew S Levey, Mark Samak; MESA: Michael G Shlipak, Joachim Ix,
Ian de Boer, Ronit Katz; MMKD: Florian Kronenberg, Barbara Kollerits, Eberhard Ritz; MRC
Older Age: Dorothea Nitsch; Mt Sinai BioMe: Girish N Nadkarni, Lili Chan, Erwin P Bottinger,
Wonsuk Oh; Nanjing CKD: Zhihong Liu, Haitao Zhang, Lihua Zhang; Nefrona: Jose M
Valdivielso, Marcelino Bermudez-Lopez, Milica Bozic, Maite Caus, Juan Miguel Diaz-Tocados;
NephroTest: Benedicte Stengel, Marie Metzger; NHANES: Yingying Sang; NIPPON DATA80:
Katsuyuki Miura, Hirotsugu Ueshima, Akira Okayama, Aya Kadota; NIPPON DATA90:
Katsuyuki Miura, Hirotsugu Ueshima, Tomonori Okamura, Aya Kadota; NRHP-URU: Laura
Sola, Alejandro Ferreiro, Jose Santiago, Pablo Rios, Liliana Gadola, Ricardo Silvariño;
Ohasama: Takayoshi Ohkubo, Michihiro Satoh, Hirohito Metoki, Masahiro Kikuya; Okinawa:
Kunitoshi Iseki; OLDW: Elizabeth Ciemens, Jeff Mohl; Pima: Robert G Nelson, Robert L
Hanson, Helen C Looker; PREVEND: Ron T Gansevoort, Lynanne M Kieneker, Stephan JL
Bakker; PSPA: Olivier Moranne, Cecile Couchoud; PSP-CKD: Nigel J Brunskill, Rupert Major,
David Shepherd, James Medcalf; Rancho Bernardo: Simerjot K Jassal, Jaclyn Bergstrom,
Joachim Ix; RCAV: Csaba P Kovesdy, Keiichi Sumida, Prabin Shrestha; REGARDS: Orlando
Gutierrez, Katharine Cheung, Paul Muntner, Titi Ilori; RENAAAL: Michelle Pena, Hiddo JL
Heerspink; SCREAM: Edouard L Fu, Carl-Gustaf Elinder, Peter Barany, Juan J Carrero, Marie
Evans; SEED: Charumathi Sabanayagam, Ching-Yu Cheng, Tien Yin Wong, Crystal Chong
Chun Yuen; SHARP: William Herrington, Natalie Staplin, Martin J Landray, Colin Baigent; SKS:
Philip Kalra, Rajkumar Chinnadurai, Darren Green, Sneeta Sinha, James Ritchie; SMART:
Frank LJ Visseren, Pascal Burger, Marielle Emmelot, Berend van Welzen; **SRR-CKD**: Marie Evans; **STOP-CKDu**: Vivekanand Jha, Oommen John, Balaji Gummidi, Arpita Ghosh;

**Sunnybrook**: David Naimark, Navdeep Tangri; **Taiwan MJ**: Chi-Pang Wen, Min-Kuang Tsai;

**Takahata**: Yoshiyuki Ueno, Tsuneo Konta, Masafumi Watanabe, Kazunobu Ichikawa; **TLGS**: Mohammadhassan Mirbolouk, Fereidoun Azizi, Farzad Hadaegh, Farhad Hosseinpanah; **UK Biobank**: Yingying Sang, Wen Shi, Dan Arking; **ULSAM**: Johan Ärnlöv, Anders Larsson, Vilma Giedraitis; **West of Scotland**: Patrick Mark, Jamie Traynor, Michael Sullivan, Jennifer Lees; **YWSCC**: Jae won Yang, Jae il Shin, Jun young Lee, Jae seok Kim; **ZODIAC**: Henk JG Bilo, Peter van Dijk, Mireille Edens, Joep Dille

**CKD-PC Steering Committee**: Josef Coresh (Chair), Shoshana H Ballew, Juan-Jesus Carrero, Ron T Gansevoort, Morgan E. Grams, Andrew S Levey, Dorothea Nitsch, Michael Shlipak, Angela Yee-Moon Wang

**CKD-PC Data Coordinating Center**: Shoshana H Ballew (Assistant Project Director), Jingsha Chen (Programmer), Josef Coresh (Co-Principal Investigator), Morgan E Grams (Co-Principal Investigator), Kunihiro Matsushita (Director), Yingying Sang (Lead Programmer), Aditya Surapaneni (Programmer)

**Funding**

The CKD Prognosis Consortium (CKD-PC) Data Coordinating Center is funded in part by a program grant from the US National Kidney Foundation and the National Institute of Diabetes
and Digestive and Kidney Diseases (R01DK100446). A variety of sources have supported enrollment and data collection including laboratory measurements, and follow-up in the collaborating cohorts of the CKD-PC. These funding sources include government agencies such as national institutes of health and medical research councils as well as foundations and industry sponsors listed in Supplemental Appendix 3.

Role of the Sponsor

The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Availability Statement: Under agreement with the participating cohorts, CKD-PC cannot share individual data with third parties. Inquiries regarding specific analyses should be made to ckdpc@jhmi.edu. Investigators may approach the original cohorts regarding their own policies for data sharing (e.g., https://sites.cscx.unc.edu/aric/distribution-agreements for the Atherosclerosis Risk in Communities Study).

Access to Data: Dr. Grams had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of Interest Disclosures: Drs. Alencar de Pinho and Stengel declare financial support from pharmaceutical companies integrating the public-private partnership of the CKD-REIN cohort: Fresenius Medical Care, GlaxoSmithKline (GSK), Vifor France, and Boeringher
Ingelheim; all grants are made to Paris Saclay University. Dr. Ämlöv reports personal fees from AstraZeneca, Boeringer Ingelheim, Novartis, and Astella, outside the submitted work. Dr. Bell reports personal fees from GSK and AstraZeneca outside the submitted work. Dr. Chalmers received research grants for the ADVANCE trial from Servier International, many years ago, and from the National Health and Medical Research Council (NHMRC) of Australia. Dr. Coresh is a scientific advisor to Healthy.io. Dr. Ebert is a member of an EAB for Bayer AG Leverkusen. Dr. Herrington reports grants from Boehringer Ingelheim and EliLilly, MRC-UK, and Kidney Research UK outside the submitted work. Dr. Jha reports other support from GSK, Zydus Cadilla, and George Clinical, and personal fees from Bayer, Boehringer Ingelheim, and AstraZeneca, outside the submitted work. Dr. Konta reports grants and personal fees from Tanabe-Mitsubishi Pharm, Daiichi-Sankyo, Chugai, Mochida, and Novartis, and personal fees from MSD, Japan Boehringer Ingelheim, Sanwa Kagaku, Dainippon-Sumitomo, Eisai, Bayer, Kowa, Kyowa-Kirin, Astellas, and Kissei outside the submitted work. Dr. Lees reports personal fees from AstraZeneca outside the submitted work. Dr. Nitsch reports grants from MRC, NIHR, and the Health Foundation outside of the submitted work. Dr. Schaeffner has received grant funding from Bayer and consulting fees from AstraZeneca; she also receives a stipend from the National Kidney Foundation for editorial word for AJKD. Dr. Shen reports personal fees from National Kidney Foundation, Healthmap Solutions, Dialco Medical and Outset Medical, and grants from Canadian Institutes of Health Research, outside the submitted work. Dr. Sinha reports grants, personal fees, and non-financial support from AstraZeneca and CSL Vifor, personal fees from Novartis, Sanofi-Genzyme, Bayer, Sanifit, Inozyme Pharma, Boehringer-Ingelheim, and Napp, grants and personal fees from GSK, and grants from Johnson & Johnson, outside the submitted work. Dr. Yatsuya reports grants from Noguchi Memorial Research Institute and grants from Aichi Health Promotion Foundation outside the submitted work. All other coauthors have nothing to disclose.
Some of the data reported here have been supplied by the United States Renal Data System. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US Government.
References


Table 1. Participant characteristics for the eGFRcr and eGFRcr-cys populations

<table>
<thead>
<tr>
<th></th>
<th>eGFRcr population</th>
<th>eGFRcr-cys population</th>
</tr>
</thead>
<tbody>
<tr>
<td>N of Cohorts</td>
<td>114</td>
<td>20</td>
</tr>
<tr>
<td>N of participants</td>
<td>27,503,140</td>
<td>721,394</td>
</tr>
<tr>
<td>Age (SD), years</td>
<td>54 (17)</td>
<td>59 (12)</td>
</tr>
<tr>
<td>Female, %</td>
<td>51%</td>
<td>53%</td>
</tr>
<tr>
<td>Male, %</td>
<td>49%</td>
<td>47%</td>
</tr>
<tr>
<td>Mean follow-up, years</td>
<td>4.8 (3.3)</td>
<td>10.8 (4.1)</td>
</tr>
</tbody>
</table>

**Medical History: Comorbid Conditions**

- Medications for hypertension, %: 17% (27%)
- Diabetes mellitus, %: 15% (9.4%)
- Former smoker, %: 13% (35%)
- Current smoker, %: 11% (11%)
- Coronary heart disease, %: 9.9% (6.3%)
- History of cancer, %: 13% (11%)
- Chronic obstructive pulmonary disease, %: 7.5% (2.4%)
- Atrial fibrillation, %: 4.5% (4.7%)
- History of heart failure, %: 3.5% (3.2%)
- History of stroke, %: 3.2% (3.5%)
- Peripheral artery disease, %: 1.6% (1.0%)

**Medical History: Vital Signs and Laboratory Studies**

- Systolic blood pressure (SD), mmHg: 126 (17) (138 (20))
- Body-mass index (SD), kg/m²: 29 (7) (28 (5))
- Total cholesterol (SD), mmol/L: 4.7 (1.3) (5.0 (1.1))
- High-density lipoprotein (SD), mmol/L: 1.3 (0.4) (1.3 (0.4))
- eGFR (SD), ml/min/1.73 m²: 90 (22) (89 (20))
- eGFRcr-cys (SD), ml/min/1.73 m²: 88 (22)
- Median albuminuria (IQR), mg/g: 11 (8-16) (9 (6-18))

*The column N is not necessarily the denominator for each characteristic. The proportion with missing data for each characteristic is shown in Table S1. For albuminuria, available data represented <50% of the analytic population: 9,067,753 (33.0%) for eGFRcr and 320,443 (44.4%) for the eGFRcr-cys population. Detailed definitions of each of these elements are provided in Supplemental Appendix 1.
### Overall

<table>
<thead>
<tr>
<th>eGFRc</th>
<th>&lt;10</th>
<th>10-29</th>
<th>30-99</th>
<th>300-999</th>
<th>1000+</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;10</td>
<td>1.8</td>
<td>2.2</td>
<td>2.2</td>
<td>2.9</td>
<td>3.1</td>
</tr>
<tr>
<td>10-29</td>
<td>1.0</td>
<td>1.3</td>
<td>1.7</td>
<td>2.2</td>
<td>2.8</td>
</tr>
<tr>
<td>30-99</td>
<td>1.3</td>
<td>1.6</td>
<td>2.0</td>
<td>2.4</td>
<td>3.1</td>
</tr>
<tr>
<td>300-999</td>
<td>1.9</td>
<td>2.0</td>
<td>2.5</td>
<td>3.2</td>
<td>3.9</td>
</tr>
<tr>
<td>1000+</td>
<td>2.8</td>
<td>3.3</td>
<td>4.1</td>
<td>5.6</td>
<td>7.9</td>
</tr>
</tbody>
</table>

#### Kidney Failure with Replacement Therapy:
- 57 cohorts; participants = 25,466,956; events = 299,729
- Heart Failure: 61 cohorts
- Myocardial infarction: 64 cohorts
- Stroke: 68 cohorts
- Cardiovascular Mortality: 76 cohorts
- Peripheral Artery Disease: 54 cohorts
- Kidney Failure: 52 cohorts

### Study size
- 2,604,028 participants, 2,604,028 events
- Myocardial infarction: 22,838,356 participants, 22,838,356 events
- Stroke: 24,746,436 participants, 24,746,436 events
- Cardiovascular Mortality: 26,022,346 participants, 26,022,346 events

### Table 2

<table>
<thead>
<tr>
<th>Overall</th>
<th>Urine albumin-creatinine ratio, mg/g</th>
<th>Urine albumin-creatinine ratio, mg/g</th>
</tr>
</thead>
<tbody>
<tr>
<td>eGFRc</td>
<td>&lt;10</td>
<td>10-29</td>
</tr>
<tr>
<td>&lt;10</td>
<td>1.8</td>
<td>2.2</td>
</tr>
<tr>
<td>10-29</td>
<td>1.0</td>
<td>1.3</td>
</tr>
<tr>
<td>30-99</td>
<td>1.3</td>
<td>1.6</td>
</tr>
<tr>
<td>300-999</td>
<td>1.9</td>
<td>2.0</td>
</tr>
<tr>
<td>1000+</td>
<td>2.8</td>
<td>3.3</td>
</tr>
</tbody>
</table>

#### Overall

<table>
<thead>
<tr>
<th>eGFRc</th>
<th>&lt;10</th>
<th>10-29</th>
<th>30-99</th>
<th>300-999</th>
<th>1000+</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;10</td>
<td>1.8</td>
<td>2.2</td>
<td>2.2</td>
<td>2.9</td>
<td>3.1</td>
</tr>
<tr>
<td>10-29</td>
<td>1.0</td>
<td>1.3</td>
<td>1.7</td>
<td>2.2</td>
<td>2.8</td>
</tr>
<tr>
<td>30-99</td>
<td>1.3</td>
<td>1.6</td>
<td>2.0</td>
<td>2.4</td>
<td>3.1</td>
</tr>
<tr>
<td>300-999</td>
<td>1.9</td>
<td>2.0</td>
<td>2.5</td>
<td>3.2</td>
<td>3.9</td>
</tr>
<tr>
<td>1000+</td>
<td>2.8</td>
<td>3.3</td>
<td>4.1</td>
<td>5.6</td>
<td>7.9</td>
</tr>
</tbody>
</table>

#### Acute Kidney Injury: 49 cohorts
- participants = 23,914,614; events = 1,408,829

#### Hospitalization: 49 cohorts
- participants = 25,426,722; events = 8,308,637

#### Peripheral Artery Disease: 54 cohorts
- participants = 24,830,784; events = 378,924
Ref: reference cell. Numbers reflect the adjusted hazard ratio compared with the reference cell. Adjustment variables included: age, sex, smoking status (current, former, never), systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, body-mass index, use of anti-hypertensive medications, and a medical history of diabetes, coronary heart disease, stroke, heart failure, atrial fibrillation, peripheral artery disease, cancer, and chronic obstructive pulmonary disease, where relevant. All models are shown in Supplemental Appendix 1. The cohorts used in these analyses are the general population and electronic health record cohorts (CKD cohorts do not have sufficient participants in the reference cells) and a missing albuminuria category was included. Sample sizes include participants who are missing albuminuria. Adjusted hazard ratios for participants missing albuminuria measures, as well as N/n for individual cells, are shown in Supplemental Table 6. The colors were determined for each outcome separately using the following rule: the percentile shaded the darkest green color corresponds to the proportion of cells in the grid without CKD (e.g., 6 out of 35 cells with eGFR ≥60 ml/min/1.73 m² and ACR <30 mg/g), and the percentile shaded the darkest red color corresponds to proportion expected to be at highest risk (e.g., 11 out of 35 cells with eGFR <15 ml/1.73 m² and ACR 1000+ mg/g). In this manner, the numbers of green and red cells are consistent across outcomes, but the patterns are allowed to differ.
**Table 2.** Adjusted hazard ratios of subsequent adverse outcomes for individuals with mild-moderate kidney disease (CKD category G3a with urine albumin-to-creatinine rate (ACR) <10 mg/g, ACR 10-29 mg/g, and missing ACR).

<table>
<thead>
<tr>
<th>Hazard Ratio (95% CI)</th>
<th>eGFRcr population</th>
<th>eGFRcr-cys population</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>eGFRcr 90-105 and ACR&lt;10</td>
<td>eGFRcr 45-59 and ACR&lt;10</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>ref 1.3 (1.2, 1.4)</td>
<td>1.6 (1.5, 1.7)</td>
</tr>
<tr>
<td>Cardiovascular mortality</td>
<td>ref 1.4 (1.3, 1.4)</td>
<td>1.7 (1.5, 1.9)</td>
</tr>
<tr>
<td>Kidney failure with replacement therapy</td>
<td>ref 12.7 (11.1, 14.6)</td>
<td>19.0 (15.6, 23.1)</td>
</tr>
<tr>
<td>Acute kidney injury</td>
<td>ref 3.5 (3.3, 3.7)</td>
<td>4.0 (3.7, 4.3)</td>
</tr>
<tr>
<td>Hospitalization</td>
<td>ref 1.3 (1.2, 1.3)</td>
<td>1.3 (1.3, 1.4)</td>
</tr>
<tr>
<td>Coronary heart disease</td>
<td>ref 1.4 (1.3, 1.5)</td>
<td>1.7 (1.6, 1.8)</td>
</tr>
<tr>
<td>Stroke</td>
<td>ref 1.4 (1.3, 1.5)</td>
<td>1.6 (1.5, 1.7)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>ref 1.6 (1.5, 1.7)</td>
<td>1.8 (1.7, 2.0)</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>ref 1.2 (1.2, 1.3)</td>
<td>1.3 (1.3, 1.4)</td>
</tr>
<tr>
<td>Peripheral artery disease</td>
<td>ref 1.5 (1.3, 1.6)</td>
<td>1.8 (1.6, 2.0)</td>
</tr>
</tbody>
</table>

**Ref: reference cell: eGFR 90-105 ml/min/1.73 m² and ACR <10 mg/g. Numbers reflect the adjusted hazard ratio compared with the reference cell. Adjustment variables included: age, sex, smoking status (current, former, never), systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, body mass index, use of anti-hypertensive medications, and a medical history of diabetes, coronary heart disease, stroke, heart failure, atrial fibrillation, peripheral artery disease, cancer, and chronic obstructive pulmonary disease, where relevant. All models are shown in Supplemental Appendix 1. The cohorts used in these analyses are the general population and electronic health record cohorts (CKD cohorts do not have sufficient participants in the reference cells) and a missing albuminuria category was included. All p-values <0.001. eGFR, estimated glomerular filtration rate. ACR, urine albumin-to-creatinine ratio. Number of cohorts are listed in Table 2 and 4, and cell-specific sample size and events are listed in Supplemental Table 6 and 12. CKD is staged into G categories and A categories, with higher categories indicating more severe disease.**
* Ref: reference cell. Numbers reflect the adjusted hazard ratio compared with the reference cell. Adjustment variables included: age, sex, smoking status (current, former, never), systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, body-mass index, use of anti-hypertensive medications, and a medical history of diabetes, coronary heart disease, stroke, heart failure, atrial fibrillation, peripheral artery disease, cancer, and chronic obstructive pulmonary disease.

<table>
<thead>
<tr>
<th>eGFRcyst</th>
<th>&lt;10</th>
<th>10 - 29</th>
<th>30 - 299</th>
<th>300+</th>
<th>&lt;10</th>
<th>10 - 29</th>
<th>30 - 299</th>
<th>300+</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause Mortality: 11 cohorts</td>
<td>692,802</td>
<td>97,006</td>
<td>0.9</td>
<td>1.2</td>
<td>1.4</td>
<td>2.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocardial Infarction: 10 cohorts</td>
<td>649,365</td>
<td>17,926</td>
<td>ref</td>
<td>1.2</td>
<td>1.4</td>
<td>1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular Mortality: 11 cohorts</td>
<td>692,322</td>
<td>25,322</td>
<td>ref</td>
<td>1.2</td>
<td>1.4</td>
<td>1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke: 9 cohorts</td>
<td>662,605</td>
<td>16,909</td>
<td>ref</td>
<td>1.2</td>
<td>1.4</td>
<td>1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney Failure with Replacement Therapy: 5 cohorts</td>
<td>630,370</td>
<td>4,306</td>
<td>ref</td>
<td>1.2</td>
<td>1.4</td>
<td>1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart Failure: 9 cohorts</td>
<td>641,298</td>
<td>27,406</td>
<td>ref</td>
<td>1.2</td>
<td>1.4</td>
<td>1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute Kidney Injury: 5 cohorts</td>
<td>630,370</td>
<td>4,062</td>
<td>ref</td>
<td>1.2</td>
<td>1.4</td>
<td>1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrial Fibrillation: 5 cohorts</td>
<td>607,102</td>
<td>37,278</td>
<td>ref</td>
<td>1.2</td>
<td>1.4</td>
<td>1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalization: 3 cohorts</td>
<td>630,489</td>
<td>464,894</td>
<td>ref</td>
<td>1.2</td>
<td>1.4</td>
<td>1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral Artery Disease: 6 cohorts</td>
<td>642,624</td>
<td>3,943</td>
<td>ref</td>
<td>1.2</td>
<td>1.4</td>
<td>1.8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Ref: reference cell. Numbers reflect the adjusted hazard ratio compared with the reference cell.
pulmonary disease, where relevant. All models are shown in Supplemental Appendix 1. The cohorts used in these analyses are the general population and electronic health record cohorts (CKD cohorts do not have sufficient participants in the reference cells) and a missing albuminuria category was included. Sample sizes include participants who are missing albuminuria. Adjusted hazard ratios for participants missing albuminuria measures, as well as N/n for individual cells, are shown in Supplemental Table 12. The colors were determined for each outcome separately using the following rule: the percentile shaded the darkest green color corresponds to the proportion of cells in the grid without CKD (e.g., 6 out of 24 cells), and the percentile shaded the darkest red color corresponds to proportion expected to be at highest risk (e.g., 5 out of 24 cells). In this manner, the numbers of green and red cells are consistent across outcomes, but the patterns are allowed to differ.
Figure 3. Hazard ratios for adverse outcomes using a continuous model of eGFR in the population with creatinine and cystatin C, comparison of the shape of associations between eGFRcr and eGFRcr-cys with outcomes.

Panel A. Associations of eGFRcr with all-cause mortality, cardiovascular mortality, all-cause hospitalizations, myocardial infarction, stroke, heart failure, atrial fibrillation, peripheral artery disease.

Panel B. Associations of eGFRcr-cys with all-cause mortality, cardiovascular mortality, all-cause hospitalizations, myocardial infarction, stroke, heart failure, atrial fibrillation, peripheral artery disease.

Panel C. Associations of eGFRcr with kidney failure with replacement therapy and acute kidney injury.

Panel D. Associations of eGFRcr-cys with kidney failure with replacement therapy and acute kidney injury.

Dots indicate that the 95% confidence interval for the hazard ratio from this spline model does not include 1.0 (which is indicated with a diamond as the reference point at eGFR 90 ml/min/1.73 m²).